April 16, 2015 | The Israeli biomed company Foamix Pharmaceuticals announced that it raised $60 million in a secondary NASDAQ offering. Foamix is the developer of a foam-based delivery method for dermatological products and drugs. Foamix was founded in 2003 by Dov Tamarkind.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments